Curis/Genentech Report Positive Phase II Results For Vismodegib
This article was originally published in The Pink Sheet Daily
Executive Summary
Curis and its partner, Roche's Genentech, plan a 2011 filing for basal cell carcinoma drug vismodegib after announcing positive mid-stage results.